

" The high linear probe with $CnTI^{TM}$ Clear enables us to improve the daily routine to expand the diagnosis."


CnTITM Clear with high frequency linear probes Higher sensitivity and resolution in CEUS


Case studies courtesy of Dirk-André Clevert, MD


Professor of Radiology Interdisciplinary Ultrasound-Center, Department of Clinical Radiology University of Munich-Grosshadern Campus, Germany


Breast Cancer with Necrosis












Transplant











Kidney without Infarction





Arterial phase



Portal-Venous phase





Late phase















Atypical Hemangioma















Hemangioma














N S E E N . esaote Н Ε

Esaote S.p.A. - sole-shareholder company - Via Enrico Melen 77, 16152 Genova, ITALY, Tel. +39 010 6547 1, Fax +39 010 6547 275, info@esaote.com

CnTI^M: The use of Contrast Agents in the USA is limited by FDA to the left ventricle opacification and to characterization of focal liver lesions Technology and features are system/configuration dependent. Specifications subject to change without notice. Information might refer to products or modalities not yet approved in all countries. Product images are for illustrative purposes only. For further details, please contact your Esaote sales representative.